Overview

Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis

Status:
Recruiting
Trial end date:
2025-03-11
Target enrollment:
Participant gender:
Summary
Evaluate long-term safety and tolerability of tofacitinib in patients with JIA, who have previously participated in tofacitinib JIA studies.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Treatments:
Tofacitinib